Bradanicline
Bradanicline (INN) (code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.
Wikipage redirect
primaryTopic
Bradanicline
Bradanicline (INN) (code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.
has abstract
Bradanicline (INN) (code name ...... r seems to be being developed.
@en
CAS number
639489-84-2
FDA UNII code
UM3821998K
IUPAC name
N-[(2S,3R)-2-(Pyridin-3-ylmeth ...... l]-1-benzofuran-2- carboxamide
@en
PubChem
thumbnail
Wikipage page ID
19,476,092
Wikipage revision ID
701,790,238
ChEMBL
molecular weight
3.61437e+2
smiles
C1CN2CCC1[C@@H]NCC4=CC5=CC=CC=C5O4
synonyms
verifiedrevid
444,128,206
hypernym
comment
Bradanicline (INN) (code name ...... and it was in phase II trials.
@en
label
Bradanicline
@en
